Editor in Chief Dr KK Aggarwal, Padma Shri Awardee                                                                               Dated:27 January,2020

Coronavirus: 99 more people under surveillance in Kerala

"Today, 99 new passengers arrived in the state.This makes a total of 179 persons under surveillance.Only seven people have any kind of symptoms.

THIRUVANANTHAPURAM: Ninety-nine more people who returned to Kerala from China on Saturday have been kept under surveillance by health officials in the state for possible exposure to novel coronavirus (nCoV), health officials said here on Saturday.

With this, a total of 179 people in the state are under surveillance. A senior health official said that 172 persons in the state are under home surveillance and the other seven are under observation at hospitals across the state....read more


Respective Governments should pay for the treatment of their Citizens trapped in China with Corona Virus: NMAs should raise the issue with respective Governments

Preeti Maheshwari the first Indian victim of pneumonia in China needs Rs. 1 crore for treatment. The Indian Government should pay. As per reports she is suffering from Corona secondary srteptococcal bacterial infection.

Unable to fund Rs. 1 crore needed for the treatment, the family has reached out to the Indian embassy in Beijing and healthcare crowd funding platforms for help, reports the Mint....read more


Forgetfulness and Age

By the time we cross 40, most of us suffer from minimal cognitive impairment and have a memory loss of very recent events or objects. This is age related and should not be confused with dementia.

This can also happen in patients who are vegetarians and vitamin B12 deficient. People often have difficulty in naming objects and name of the people....read more


Health Sutras By Dr K K Aggarwal

In diarrhea, one loose motion is equivalent to 200 ml of fluid loss.


Medbytes

       


Healthcare News Monitor

Srepta shares fall 4% after FDA documents show safety concern about drug
ET Healthworld Carl O'Donnell

Shares of Sarepta Therapeutics Inc were down around 4% Wednesday after the U.S. Food and Drug Administration revealed documents detailing concerns it had about the safety and efficacy of one of the company's recently approved Duchenne muscular dystrophy (DMD) drugs. The drug, Vyondys 53, also known as golodirsen, was originally rejected by the FDA last year before the agency reversed that decision in December and approved it. It was the second controversial drug approval for Sarepta. The company saw its first drug, Exondys 51, which also treats DMD, approved in 2016 despite concerns raised by experts about its effectiveness.

Cipla gets USFDA observations for its Goa facility
ET Healthworld PTI

Drug firm Cipla on Wednesday said it has received observations from the USFDA for its Goa manufacturing facility. It further said that the developments will not have any material impact on the company's US business at this stage. "The United States Food and Drug Administration (USFDA) has classified the inspection conducted at its Goa manufacturing facility from 16-27 September 2019 as Official Action Indicated (OAI). The company does not believe that this will have any material impact on the US business at this stage," the drug major said in an exchange filing. Cipla further said it has a strong track record of maintaining the highest standard of compliance and will work closely with the agency to comprehensively address the observations received.

J&J misses revenue estimates as blockbuster drugs disappoint
ET Healthworld PTI

Johnson & Johnson narrowly missed quarterly revenue estimates on Wednesday as sales of its blockbuster psoriasis medicine Stelara and cancer drug Imbruvica fell short of expectations. Revenue at J&J's pharmaceuticals unit, which also makes antidepressant Spravato and plaque psoriasis drug Tremfya, rose 3.5% to $10.55 billion in the fourth quarter, missing the average estimate of $10.63 billion, according to two analysts polled by Refinitiv. The company said it expects full-year 2020 adjusted earnings per share in the range $8.95 to $9.10. Litigation expenses fell to $264 million in the fourth quarter, from $1.29 billion a year ago.

Delhi: RML Hospital Declared Nodal Hospital To Manage Cases Of Novel Coronavirus If Detected
Medical Dialogues

The Centre-run Dr Ram Manohar Lohia (RML) Hospital has been declared as a nodal Hospital to manage the cases of novel coronavirus (nCoV) if detected in India. The development comes amid an outbreak of the novel coronavirus (nCoV) in China and reports that Indian nurses in Saudi Arabia suspected to have tested positive in Saudi Arabia for the deadly disease Speaking to ANI, Dr Meenakshi Bhawadwaj, Medical Superintendent of RML said, "We have built up a dedicated isolation coronavirus isolation ward. Our team of doctors and nurses have been instructed to monitor such patients if the need arises. Also, the Centre is making all important actions for preventive measure. However, as of now, no case of coronavirus has been reported in India so far." "As a part of preventive measure against coronavirus infection, people are advised to cover their mouth with the mask, maintain a good standard of hand hygiene and should avoid travelling in crowded places. Any kind of fever, cough, cold and illness should be reported immediately to the nearest doctor," said Dr Bharadwaj. The Health Secretary Preeti Sudan on Wednesday informed that as on January 22, 12,828 passengers from 60 flights have been screened for novel coronavirus symptoms, and no passenger has been detected in India so far.